Please assess the completion status of the following clinical trial:

Trial Title: Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and the willingness to sign an informed consent document~* Own a smartphone that uses Android or Apple iOS operating systems~* Participant must have one of the following:~  * Individuals with newly-diagnosed, treatment naive PDAC - all stages (applicable to Stage 1 only), or~ * Individuals with at least one of the following family phenotype and age will be included:~    * Two or more relatives with PDAC on the same side of the family, where 2 PDAC affected individuals are first-degree related (FDR) AND at least one PDAC-affected individual is an FDR of the subject; Age \>= 50 years OR 10 years before onset in family~   * Two affected FDR with PDAC; Age \>= 50 years OR 10 years before onset of an FDR~   * Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic; Age \>= 50 years OR 10 years before onset of an FDR or second-degree relative (SDR)~   * Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A; Age \>= 50 years~   * Known mutation carrier for STK11 (Peutz-Jeghers syndrome); Age \>= 50 years~   * Lynch syndrome (hereditary nonpolyposis colorectal cancer \[HNPCC\]) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM; Age \>= 50 years OR 10 years before onset of an FDR or SDR~   * Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis; Age \>= 50 years~Exclusion Criteria:~* Any medical conditions that in the opinion of the investigators would compromise participant safety and/or the integrity of the data

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Observational (HRV monitoring, questionnaire) (Type: None): Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.

Based on this trial design, predict the completion outcome and termination type (if applicable).